On August 1, 2015 that agreement for a license grant of intellectual property to Regen Biopharma,Inc. (“Regen”) by Benitec Australia Limited (“Benitec”) dated August 5, 2013 (“Agreement”) was amended as follows:
Any License Fees or Milestone Payments ( as those terms are defined in the Agreement”) to be paid subsequent to April 6, 2015 may be paid in the common stock of Regen.
...so sad!
such common stock would be issued at Regen Biopharma’s discretion and, in the event that Regen Biopharma doesn’t have enough authorized shares available to issue, Regen Biopharma may increase the authorized shares so as to allow payment to Benitec Australia.
AI
